CO2023000118A2 - Composiciones y métodos para el tratamiento de la apnea obstructiva del sueño (aos) - Google Patents

Composiciones y métodos para el tratamiento de la apnea obstructiva del sueño (aos)

Info

Publication number
CO2023000118A2
CO2023000118A2 CONC2023/0000118A CO2023000118A CO2023000118A2 CO 2023000118 A2 CO2023000118 A2 CO 2023000118A2 CO 2023000118 A CO2023000118 A CO 2023000118A CO 2023000118 A2 CO2023000118 A2 CO 2023000118A2
Authority
CO
Colombia
Prior art keywords
compositions
treatment
osa
methods
sleep apnea
Prior art date
Application number
CONC2023/0000118A
Other languages
English (en)
Spanish (es)
Inventor
Sudhanshu Agarwal
Mark Robert Bleackley
Joel Bradley Latham
Original Assignee
Incannex Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902368A external-priority patent/AU2020902368A0/en
Application filed by Incannex Healthcare Ltd filed Critical Incannex Healthcare Ltd
Publication of CO2023000118A2 publication Critical patent/CO2023000118A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2023/0000118A 2020-07-09 2023-01-06 Composiciones y métodos para el tratamiento de la apnea obstructiva del sueño (aos) CO2023000118A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020902368A AU2020902368A0 (en) 2020-07-09 A method of treatment
PCT/AU2021/050734 WO2022006636A1 (en) 2020-07-09 2021-07-09 Compositions and methods for the treatment of obstructive sleep apnoea (osa)

Publications (1)

Publication Number Publication Date
CO2023000118A2 true CO2023000118A2 (es) 2023-04-17

Family

ID=79553355

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0000118A CO2023000118A2 (es) 2020-07-09 2023-01-06 Composiciones y métodos para el tratamiento de la apnea obstructiva del sueño (aos)

Country Status (8)

Country Link
US (1) US20230310364A1 (https=)
EP (1) EP4178568A4 (https=)
JP (1) JP7796718B2 (https=)
AU (1) AU2021306424A1 (https=)
CA (1) CA3182528A1 (https=)
CO (1) CO2023000118A2 (https=)
IL (1) IL299212A (https=)
WO (1) WO2022006636A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025520386A (ja) * 2022-06-21 2025-07-03 アプニメッド，インコーポレイテッド（デラウェア） カンナビノイドおよびカルボニックアンヒドラーゼ阻害剤の組合せを用いた睡眠時無呼吸を治療する方法
EP4626410A1 (en) * 2022-11-29 2025-10-08 Incannex Healthcare Limited A method of treating obstructive sleep apnoea (osa)
WO2025107039A1 (en) * 2023-11-23 2025-05-30 Incannex Healthcare Limited Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule
WO2025191322A1 (en) * 2024-03-11 2025-09-18 Mousavi Mirzaei Seyed Mohammad Therapeutic composition for improving symptoms of obstructive sleep apnea

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3090743A1 (en) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES
CA3126772A1 (en) * 2018-01-29 2019-08-01 Evero Compositions and methods for treating obstructive sleep apnea
WO2019180706A1 (en) * 2018-03-19 2019-09-26 Bol Pharma Ltd. Methods and compositions for treating epilepsy and associated disorders
US20240189328A1 (en) * 2021-04-16 2024-06-13 Apnimed, Inc. (Delaware) Combination of norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea

Also Published As

Publication number Publication date
IL299212A (en) 2023-02-01
CA3182528A1 (en) 2022-01-13
EP4178568A1 (en) 2023-05-17
JP2023533289A (ja) 2023-08-02
WO2022006636A1 (en) 2022-01-13
JP7796718B2 (ja) 2026-01-09
AU2021306424A1 (en) 2023-01-19
EP4178568A4 (en) 2024-10-16
US20230310364A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
CO2023000118A2 (es) Composiciones y métodos para el tratamiento de la apnea obstructiva del sueño (aos)
PY2040196A (es) Uso de cannabidiol en el tratamiento del síndrome de dravet
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
CL2012001844A1 (es) Metodo para el tratamiento del sindrome de apnea obstructiva del sueño que comprende la administración de un inhibidor de la anhidrasa carbónica y un agente adicional seleccionado de modafinilo, agente sedante no benzodiazepina, y combinaciones de los mismos; una formulacion farmacéutica; una preparacion farmaceutica empaquetada.
JOP20210274A1 (ar) طرق لإعطاء مثبط vmat2 معين
MX2022013081A (es) Compuestos para el tratamiento de sars.
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
MX383365B (es) Metodos para tratar inflamacion e hipertension con eliminadores de gama-cetoaldehidos.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
ECSP22077573A (es) Método para el tratamiento de afecciones asociadas a covid-19
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
PE20230996A1 (es) Metodo para el tratamiento de afecciones asociadas a covid-19
AR088182A1 (es) MODULADORES ALOSTERICOS POSITIVOS DE mGluR5 FARMACEUTICAMENTE ACEPTABLES Y METODOS DE IDENTIFICACION DE LOS MISMOS
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
MX2024007868A (es) Un metodo para reducir la emision de amoniaco de los animales.
MX2022006884A (es) Composicion para cicatrizacion de heridas cronicas y aplicaciones de la misma.
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek
CL2020003396A1 (es) Metodo de preparacion de una nanoemulsion que comprende exudados de psoralea glandulosa o escallonia illinita o la mezcla de ellos utiles en el tratamiento de patogenos en plantas.